At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jul 20, 2026 at 19:31 ET
Telix reported Q2 2026 revenue of $247M, up 21% YoY and 7% QoQ, driven by Precision Medicine growth. The company expects FY 2026 revenue and other income to exceed $1B, tracking the upper end of guidance. R&D guidance was raised to $230-270M to accelerate pipeline programs, and a $600M convertible bond refinancing was completed.
- Q2 2026 revenue $247M, up 21% YoY and 7% QoQ
- Precision Medicine revenue $202M, up 30% YoY and 9% QoQ
- FY 2026 revenue guidance tracking upper end of $950M-$970M, plus $40M non-refundable Regeneron payment
- R&D expenditure guidance raised to $230M-$270M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access